Phase 3 trials in CLL have demonstrated improved progression-free survival with BTK inhibitors over standards of care at the time of study initiation [16,17,18,19,20]; however, they have not yet been directly compared to fixed-duration venetoclax-based regimens that have also demonstrated improved efficacy over standards of care in CLL [21,22]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.